Literature DB >> 7949177

Identification of a malignant counterpart of the monocyte-dendritic cell progenitor in an acute myeloid leukemia.

F Santiago-Schwarz1, D L Coppock, A A Hindenburg, J Kern.   

Abstract

Myeloblasts derived from the peripheral blood of a patient with acute myelogenous leukemia (ORL47) were found to represent the malignant counterpart of the newly elucidated monocyte-dendritic cell colony-forming unit (mono-DC-CFU). The specific cytokine conditions require to achieve intermediate and terminal maturation of DCs and monocytes from these progenitors were defined. With tumor necrosis factor (TNF) + granulocyte-macrophage colony-stimulating factor (GM-CSF) + stem cell factor treatment numerous colony-like clusters developed. In contrast with normal DC development, further advancement of mono-DC-CFU and terminal DC maturation from the leukemic cells were dependent on the addition of interleukin-6. Functional and phenotypic analysis showed that the capacity to differentiate was maintained fully in the DC compartment, but only partially in the monocyte compartment, as judged by the lack of CD14 surface expression. Cells found at intermediate stages of DC development were potent stimulators of a mixed leukocyte reaction, a function usually attributed to mature DCs. As previously shown for normal DC development, antibodies to TNF alpha and GM-CSF blocked proliferative responses and DC growth. The importance of these observations in the classification of leukemias, normal DC development, and potential clinical strategies is discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7949177

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  The plasticity and potential of leukemia cell lines to differentiate into dendritic cells.

Authors:  Qingwei Guo; Leling Zhang; Fu Li; Guosheng Jiang
Journal:  Oncol Lett       Date:  2012-07-25       Impact factor: 2.967

2.  Expression of cellular adhesion molecules in Langerhans cell histiocytosis and normal Langerhans cells.

Authors:  J H de Graaf; R Y Tamminga; W A Kamps; W Timens
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

Review 3.  Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia.

Authors:  Daniel Christoph Amberger; Helga Maria Schmetzer
Journal:  Transfus Med Hemother       Date:  2020-11-05       Impact factor: 3.747

4.  In vitro induction of potent tumor-specific cytotoxic T lymphocytes using TLR agonist-activated AML-DC.

Authors:  Maryam Nourizadeh; Farimah Masoumi; Ali Memarian; Kamran Alimoghaddam; Seyed Mohammad Moazzeni; Marjan Yaghmaie; Jamshid Hadjati
Journal:  Target Oncol       Date:  2013-07-14       Impact factor: 4.493

5.  Generation of dendritic cells from peripheral blood of patients at different stages of chronic myeloid leukemia.

Authors:  C Zheng; P Pisa; O Stromberg; E Blennow; M Hansson
Journal:  Med Oncol       Date:  2000-11       Impact factor: 3.064

6.  Optimization and limitation of calcium ionophore to generate DCs from acute myeloid leukemic cells.

Authors:  Thanh-Nhan Nguyen Pham; Bo-Hwa Choi; Hyun-Kyu Kang; Chun-Chi Jin; Nguyen Hoang Tuyet Minh; Sang-Ki Kim; Jong-Hee Nam; Deok-Hwan Yang; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Ik-Joo Chung; Je-Jung Lee
Journal:  Cancer Res Treat       Date:  2007-12-31       Impact factor: 4.679

7.  Clinical uses of GM-CSF, a critical appraisal and update.

Authors:  Martha Arellano; Sagar Lonial
Journal:  Biologics       Date:  2008-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.